GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » TherapeuticsMD Inc (STU:29TA) » Definitions » Institutional Ownership

TherapeuticsMD (STU:29TA) Institutional Ownership : 6.89% (As of Jun. 07, 2024)


View and export this data going back to 2014. Start your Free Trial

What is TherapeuticsMD Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, TherapeuticsMD's institutional ownership is 6.89%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, TherapeuticsMD's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, TherapeuticsMD's Float Percentage Of Total Shares Outstanding is 73.06%.


TherapeuticsMD Institutional Ownership Historical Data

The historical data trend for TherapeuticsMD's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TherapeuticsMD Institutional Ownership Chart

TherapeuticsMD Historical Data

The historical data trend for TherapeuticsMD can be seen below:

2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31 2024-04-30 2024-05-31
Institutional Ownership 10.36 9.95 7.62 7.62 6.96 6.95 6.94 6.91 6.89 6.89

TherapeuticsMD Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


TherapeuticsMD (STU:29TA) Business Description

Traded in Other Exchanges
Address
951 Yamato Road, Suite 220, Boca Raton, FL, USA, 33431
TherapeuticsMD Inc is a major drug manufacturing with a focus on creating and commercializing products targeted exclusively for women. The company intends to commercialize advanced hormone therapy pharmaceutical products. TherapeuticsMD's drug candidates that have completed clinical trials are designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis, and discomfort. The company relies on third parties for the production of clinical and commercial quantities of its drug candidates.

TherapeuticsMD (STU:29TA) Headlines

No Headlines